Core Viewpoint - Keros Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following significant stock price declines related to safety concerns in its clinical trials [1][2][3]. Group 1: Company Actions and Stock Performance - On December 12, 2024, Keros announced a voluntary halt in dosing for certain treatment arms in the TROPOS trial due to safety concerns, leading to a stock price drop of $50.22 per share, or 73.15%, closing at $18.43 [2]. - On January 15, 2025, Keros further halted all dosing in the TROPOS trial based on ongoing safety reviews, resulting in an additional stock price decline of $2.06 per share, or 16.51%, closing at $10.42 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Keros investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - The article discusses an ongoing investigation related to Keros Therapeutics, Inc. (KROS) and highlights potential financial losses incurred by investors due to the company's actions [1] Group 1 - The investigation is being conducted by Levi & Korsinsky, focusing on whether Keros Therapeutics misled investors regarding its financial performance and business prospects [1] - Investors who have lost money on Keros Therapeutics are encouraged to contact the law firm for assistance in the investigation [1] - The article emphasizes the importance of understanding the implications of the investigation for current and potential investors in Keros Therapeutics [1]

Core Viewpoint - Keros Therapeutics, Inc. (KROS) is currently under investigation by Bronstein, Gewirtz & Grossman, LLC, which is encouraging stockholders to reach out for more information regarding the investigation [1] Group 1 - The investigation pertains to potential violations of securities laws by Keros Therapeutics [1] - Stockholders are being urged to contact the firm to understand the implications of the investigation [1] - The investigation may impact the stock performance and investor sentiment towards Keros Therapeutics [1]

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the global development and commercialization license agreement with Takeda (NYSE:TAK) to advance elritercep ...

Shareholders that lost money on Keros Therapeutics, Inc. (KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS ...

A downtrend has been apparent in Keros Therapeutics, Inc. (KROS) lately with too much selling pressure. The stock has declined 36.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indic ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation ...

Keros Therapeutics, Inc. (KROS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates ...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out ...

Group 1 - The article discusses an active investigation regarding Keros Therapeutics, Inc. for investors who may have lost money on their investments [1] Group 2 - Investors are encouraged to contact Levi & Korsinsky for assistance related to their losses in Keros Therapeutics, Inc. [1]